Journey Medical's Emrosi Inflection: Fortress Biotech's Subsidiary Flips to Positive EBITDA
Prescription momentum and payer traction drive a breakout quarter for the dermatology portfolio
FBIO · Earnings Call · 2026-08-12
A Breakout Quarter Within the Fortress Franchise
Fortress Biotech (FBIO) reported second-quarter 2026 results via its subsidiary Journey Medical, and the numbers tell a clear story of operational acceleration. While the parent's consolidated fundamentals still reflect its broader biotech platform, the operating subsidiary delivered a genuine inflection: “we generated positive EBITDA in the second quarter” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-08-12 — a marked improvement from the prior-year net loss. Total product revenue rose 23% year-over-year to $18.5 million, driven almost entirely by New prescriptions for Emrosi, the oral rosacea treatment that continues to accelerate. The commercial momentum is unmistakable. Emrosi prescriptions reached approximately 36,000 in Q2, up 20% sequentially from Q1, with the growth increasingly driven by depth rather than just breadth. Management highlighted that “Emrosi prescriptions totaled approximately 36,000 in the second quarter, up from about 30,000 total prescriptions in the first quarter” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-08-12. That acceleration is supported by a rapidly expanding prescriber base — now over 4,500 unique writers, up more than 40% from year-end 2025 — and by improving new prescribers engagement.Payer Access: The Long Game Pays Off
The critical driver of revenue quality is reimbursement. Journey Medical has now secured agreements with all top-three GPOs, unlocking access to over 169 million commercial lives. The company's focus is on converting that access into high-quality formularly coverage — meaning a single step edit or better. Progress is tangible: the percentage of lives with such coverage rose from 34% in Q1 to roughly 38% currently, and a large national health plan added Emrosi to its formulary in early August. Management remains confident that ASP will continue to improve through the back half of the year, as “you'll see good progress from... Q4 last year, Q1 to Q2, and our expectation is that we'll continue to gain better ASPs as more reimbursement from our payer strategy gets implemented” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-08-12. This is a recurring theme. On the prior call in November 2025, management noted “peak coverage 12 to 18 months out” — Louis Donati, Market Access Lead · 2025-03-26 — and the current quarter suggests they are hitting the upper end of that trajectory. The company is also actively negotiating down utilization management barriers, including the possibility of look-back periods, to further reduce friction.Operational Leverage and New Initiatives
Beyond Emrosi, Journey Medical is layering on incremental growth drivers. The company hired five additional dermatology sales representatives in Q2, and launched a new niche product, Eurax Cream (crotamiton 10%), for pruritus. These moves are designed to leverage the existing commercial infrastructure. CFO Joseph Benesch noted that while SG&A will step up modestly in Q3/Q4 for marketing programs, overall SG&A as a percentage of revenue should remain consistent. This discipline is reflected in the financials: operating expenses increased less than 1% year-over-year, even as revenue grew 23%. The consolidated parent metrics show a dramatic spike in operating income and net income in the latest quarter, but that is largely driven by non-recurring items at the Fortress level. More relevant is Journey Medical's cash position, which stood at $25.6 million at quarter-end, up from $24.1 million at year-end 2025. The subsidiary is approaching sustained profitability on an EBITDA basis.A Cross-Call Confirmation
The current quarter's results align with the trajectory management has been telegraphing. In the November 2025 call, Claude Maraoui boasted “we've gone from approximately 7,400 prescriptions in Q2 all the way up to about 18,200 prescriptions in Q3” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2025-11-12 — and that momentum has only compounded. The company's own keyword trajectory for 20262 shows consistent basis as a recurring theme, and the fundamental data confirms steady top-line growth for the parent. For Fortress Biotech shareholders, the subsidiary's inflection is the key signal.The setup is classic: a specialty pharma story moving from launch to commercialization, with prescriber breadth and payer tailwinds feeding accelerating revenue. The risk remains competition and reimbursement timing, but the evidence so far points to a breakout that is on track.We are delivering on our goal to generate positive EBITDA for the remainder of the year... With the market momentum building, our payer coverage continues to improve as well.